Minocyclin in Ulcerative Colitis as Added on Therapy
Status:
RECRUITING
Trial end date:
2028-08-20
Target enrollment:
Participant gender:
Summary
Ulcerative colitis (UC) is considered a subcategory of inflammatory bowel disease and the exact cause of ulcerative colitis remains undetermined. the condition appears to be related dysregulated immune response and consequent activation of inflammatory cascades, which are often affected by genetic susceptibility and environmental factors, and 20% to 40% of patients with UC also exhibit extraintestinal manifestations involving the joints, skin, eyes, or hepatobiliary tract
Phase:
PHASE2
Details
Lead Sponsor:
Mostafa Bahaa
Collaborators:
Amira Fawzy Mohamed Mashaly, Clinical Pharmacy Demonstrator, Faculty of Pharmacy- Horus University Mounir Hussein Bahgat Internal Medicine Department Mansoura University Tanta University